# Humanin: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on humanin — the first mitochondrial-derived peptide. Deep preclinical cytoprotection data, intriguing human biomarker correlations, zero interventional human trials, and a real tumor-promotion caveat.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Humanin is a scientifically legitimate endogenous mitochondrial-derived peptide with a well-characterized, multi-pathway cytoprotective mechanism and strong *preclinical* support in animals — plus genuinely intriguing human *observational* longevity correlations. But there has **never been an interventional human trial**, so its highest evidence grade for any human-relevant efficacy claim is **C (preclinical)**. Layered on top is an animal-demonstrated tumor-promotion signal and a U-shaped human risk association. It is not FDA-approved and is prohibited in sport under WADA Category S0.[1](https://peptidevox.com/#r1)[24](https://peptidevox.com/#r24)

Humanin (HN) is a 24-amino-acid peptide and the first identified member of the mitochondrial-derived peptide (MDP) family — encoded within the 16S rRNA region of the mitochondrial genome and discovered in 2001 while screening for factors that protect neurons from amyloid-β toxicity.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) It is marketed in longevity and biohacking circles as a neuroprotective, anti-aging peptide. Its mechanism is real and well-studied; its proof in humans does not exist. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Humanin is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published (almost entirely animal) literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is humanin and how does it work?

Humanin is translated from a short open reading frame within the mitochondrial 16S rRNA region, making it the founding member of the MDP family that also includes MOTS-c and the SHLPs.[1](https://peptidevox.com/#r1)[18](https://peptidevox.com/#r18) Substituting glycine for serine at position 14 yields S14G-humanin, or "HNG," which is roughly 1,000-fold more potent than wild-type humanin and is the form used in most experiments.[5](https://peptidevox.com/#r5)[1](https://peptidevox.com/#r1) Key residues are well mapped: F6 and K21 govern IGFBP-3 binding, C8 is required for BAX/tBID binding, and a cluster including L9–L11, P19 and V20 governs the secretion needed for cytoprotection.[2](https://peptidevox.com/#r2)

The mechanism — all of it preclinical — runs through three convergent cytoprotective pathways. First, humanin binds insulin-like growth-factor-binding protein-3 (IGFBP-3) at its C-terminal domain, interfering with importin-β binding and suppressing IGFBP-3-mediated, caspase-dependent apoptosis; this was the original 2003 mechanistic finding and the link the field used to predict effects on glucose homeostasis via the IGF/insulin axis.[2](https://peptidevox.com/#r2) Second, humanin binds the pro-apoptotic Bcl-2-family proteins BAX, tBID and BimEL, preventing BAX translocation to mitochondria and blocking the intrinsic apoptotic cascade — an effect specific to BAX-dependent death.[2](https://peptidevox.com/#r2) Third, it signals through a trimeric receptor (CNTFR-α / gp130 / WSX-1) to activate JAK2/STAT3 and drive AKT and ERK1/2; notably, in aged but not young mouse hippocampus, humanin increased AKT and ERK1/2 phosphorylation, an age-dependent in-vivo effect.[3](https://peptidevox.com/#r3) Native humanin's circulating half-life is only about 30 minutes, which is why the longer-acting, far more potent HNG analog is used experimentally; as a peptide it has negligible oral bioavailability, and no human pharmacokinetic data exist.[1](https://peptidevox.com/#r1)[24](https://peptidevox.com/#r24)

## What is the evidence by indication?

The orientation point is decisive: there are no human randomized controlled trials, no Phase 1/2 interventional trials, and no completed clinical endpoints for exogenous humanin or HNG in any indication — a fact you can verify against the empty interventional record on registries such as [ClinicalTrials.gov](https://clinicaltrials.gov/search?term=humanin).[24](https://peptidevox.com/#r24) Every efficacy claim below is preclinical (Grade C) unless it is an observational human biomarker correlation (association, not proof of benefit).

  Humanin evidence by indication

    IndicationBest evidenceGrade

    Neuroprotection / cognitive aging / Alzheimer'sRescue of neurons from amyloid-β in vitro; HNG ameliorates mouse stroke (MCAO); human SNP & CSF biomarker correlationsC (preclinical) + observational biomarker
    Longevity / healthspanTransgenic C. elegans lived ~7.3% longer; higher levels in children of centenarians — but midlife HNG did NOT extend mouse lifespanC (model organism) + observational
    Metabolic / insulin sensitivityAnimal/in-vitro improvement in insulin sensitivity; chronic HNG reduced visceral fat, raised lean mass, lowered IGF-I in miceC (preclinical)
    CardioprotectionHNG protects mouse heart against pressure-overload & STZ cardiac dysfunction; mixed human U-shaped associationC (preclinical) + observational
    Inflammation (asthma, gout, retina)HNG reduces airway, gouty and retinal inflammation in animal/cell models onlyC (preclinical)

Neuroprotection is humanin's founding role — rescue of neurons from amyloid-β toxicity in vitro, with HNG ameliorating cerebral infarction and suppressing inflammatory cytokines in a mouse middle-cerebral-artery-occlusion stroke model, and preventing age-related cognitive decline in middle-aged mice.[9](https://peptidevox.com/#r9)[4](https://peptidevox.com/#r4) The human signal is purely observational: Alzheimer's patients have lower CSF humanin (a tiny sample), and the mitochondrial SNP rs2854128 associates with roughly 15% lower circulating humanin and accelerated cognitive aging in about 16,000 older adults, with a more pronounced effect in African-American ancestry.[1](https://peptidevox.com/#r1)[4](https://peptidevox.com/#r4) That is correlation, not evidence that giving humanin treats dementia.

The longevity narrative deserves a careful read. Transgenic humanin-overexpressing C. elegans lived about 7.3% longer in a daf-16/FOXO-dependent manner, humanin declines with age across species, and circulating levels are higher and more sustained in children of centenarians than in children of non-centenarians.[1](https://peptidevox.com/#r1)[19](https://peptidevox.com/#r19) But these are associations in tiny samples — and crucially, in the very mouse-healthspan experiment that drives the longevity story, midlife HNG (4 mg/kg IP twice weekly for 14 months) did *not* significantly extend lifespan at that dose.[1](https://peptidevox.com/#r1) Metabolic and cardioprotective effects are similarly preclinical: chronic HNG reduced visceral fat, increased lean mass and lowered IGF-I in mice, and S14G-humanin protected the mouse heart against pressure-overload and streptozotocin-induced dysfunction.[6](https://peptidevox.com/#r6)[7](https://peptidevox.com/#r7)[8](https://peptidevox.com/#r8) Anti-inflammatory effects in asthma, gout and retinal models are all animal or cell-based.[10](https://peptidevox.com/#r10)[11](https://peptidevox.com/#r11)[12](https://peptidevox.com/#r12)

Proven vs hyped
Proven in humans: nothing — there is not a single interventional human trial. Intriguing but unproven: the human longevity and cognitive correlations, which are association in small samples. Hyped: humanin marketed as a longevity or neuroprotective "therapy" in people, which extrapolates from animals. One of its own pivotal mouse studies failed to extend lifespan.[1](https://peptidevox.com/#r1)

## What doses appear in the literature?

Reported strictly as information, not a protocol — and unlike most peptides, humanin has no human dose at all. There is no established human dose, route or schedule; the figures below are animal experimental doses, reported for completeness.[24](https://peptidevox.com/#r24) The route in animals is parenteral, almost always intraperitoneal injection in rodents, because the peptide structure precludes meaningful oral absorption.[1](https://peptidevox.com/#r1) The pivotal mouse healthspan study used HNG at 4 mg/kg IP twice weekly for 14 months, starting at 18 months of age in female C57BL/6N mice.[1](https://peptidevox.com/#r1) Most research uses the HNG (S14G) analog rather than native humanin, because native humanin's roughly 30-minute half-life and 1,000-fold lower potency make it impractical.[1](https://peptidevox.com/#r1)[5](https://peptidevox.com/#r5) No clinical reconstitution standard exists because there is no clinical product; material sold online is unregulated research chemical of unverified identity and purity.[21](https://peptidevox.com/#r21)

## How safe is humanin?

There are no human safety data at all — with zero interventional human exposure, there is no characterized human adverse-event profile, no PK, and no drug-interaction data.[24](https://peptidevox.com/#r24) The principal theoretical risk, and the one with the most animal support, is tumor-promotion and chemoresistance. Humanin's core anti-apoptotic, pro-survival biology is exactly what aggressive tumors exploit: exogenous humanin protected triple-negative breast cancer cells from apoptosis, promoted tumor progression, stimulated spontaneous lung metastases and impaired chemotherapy's anti-metastatic effect, while silencing humanin did the opposite.[14](https://peptidevox.com/#r14) In glioblastoma, humanin drives progression and angiogenesis via the integrin-αV/TGF-β axis and facilitates chemoresistance, with silencing re-sensitizing cells to chemotherapy.[15](https://peptidevox.com/#r15)[16](https://peptidevox.com/#r16) The findings are mixed, but the pro-tumor signal is real and unresolved. Paradoxically, humanin also protects normal tissues from chemotherapy toxicity in animals — the same property that can shield tumors.[13](https://peptidevox.com/#r13)

Two further cautions matter. Humanin-overexpressing mice were about 12% shorter and 10% lighter with roughly 46% smaller litters, pointing to growth and fertility trade-offs from chronic IGF-I-axis suppression.[1](https://peptidevox.com/#r1) And in hemodialysis patients, both abnormally low and abnormally high circulating humanin associated with higher mortality and cardiovascular risk — a U-shaped relationship that argues against assuming "more humanin is better."[17](https://peptidevox.com/#r17) By extrapolation, theoretical contraindications include active or prior malignancy, pregnancy and lactation, and pediatric use; none are formally established because no human use is sanctioned. As with all research-chemical peptides, product-quality risk — unverified composition, sterility and endotoxin status — is a concrete additional hazard.[21](https://peptidevox.com/#r21)

## What is the FDA and WADA status in 2026?

Humanin is not an FDA-approved drug — no NDA or BLA for any indication. It is not an approved compounding bulk substance: it does not appear on the FDA 503A bulk-substances list, and there is no 503B outsourcing-facility status. It is distributed only as a research chemical labeled "for research use only — not for human consumption," and selling or using it for human administration is outside FDA's lawful framework, particularly as the FDA has tightened oversight of research peptides generally through 2025–2026.[21](https://peptidevox.com/#r21)[23](https://peptidevox.com/#r23) It is not a DEA-controlled substance.

For athletes the picture is unambiguous despite humanin not being individually named on the 2026 Prohibited List. Category S0 (Non-Approved Substances) is a catch-all that prohibits any pharmacological substance not approved by any governmental health authority for human therapeutic use — explicitly including pre-clinical or clinical-development drugs and research-chemical peptides. Humanin and HNG therefore fall under S0 and are prohibited at all times, in and out of competition.[20](https://peptidevox.com/#r20)[22](https://peptidevox.com/#r22) Legitimate laboratory research remains lawful under proper oversight; the prohibitions concern human therapeutic administration.[21](https://peptidevox.com/#r21)

**Bottom line.** Humanin pairs a coherent, multi-pathway preclinical mechanism and genuinely interesting human longevity correlations with a near-total absence of human proof — not a single interventional trial, no human efficacy, no PK, no safety profile. From a root-cause, mitochondrial-health lens the more defensible reading is that humanin is today best viewed as a biomarker of mitochondrial and metabolic resilience and a target for understanding healthy aging, with exogenous administration remaining experimental, unapproved and not advisable outside controlled research — especially for anyone with cancer history, during pregnancy, or for athletes (WADA S0). Verdict: promising mechanism, real safety questions, zero clinical validation — graded C. Regulatory facts here are current as of June 2026 and should be re-verified as FDA peptide oversight evolves.

---
Source: https://peptidevox.com/peptide-encyclopedia/humanin
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt